Use of Hydroxocobalamin (Vitamin B12a) in Patients With Vasopressor Refractory Hypotension After Cardiopulmonary Bypass: A Case Series

Sarah Armour, Trygve K. Armour, William R. Joppa, Simon Maltais, James A. Nelson, Erica Wittwer

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Hydroxocobalamin (vitamin B12a) is an emerging treatment for vasoplegic syndrome (VS) associated with cardiopulmonary bypass (CPB). Given its cost and scarcity, an institutional guideline for its use as a rescue treatment in cases of suspected VS was developed. Hemodynamic variables and vasopressor requirements were reviewed for a series of 24 post-CPB patients who received B12a. Favorable changes in hemodynamic parameters and vasopressor requirements were seen after B12a administration although guideline criteria for VS were inconsistently met. These findings support the continued study of B12a in patients with CPB-associated VS.

Original languageEnglish (US)
JournalAnesthesia and analgesia
Volume129
Issue number1
DOIs
StatePublished - Jul 1 2019

Fingerprint

Vasoplegia
Hydroxocobalamin
Cardiopulmonary Bypass
Vitamins
Hypotension
Hemodynamics
Guidelines
Costs and Cost Analysis
Therapeutics

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Use of Hydroxocobalamin (Vitamin B12a) in Patients With Vasopressor Refractory Hypotension After Cardiopulmonary Bypass : A Case Series. / Armour, Sarah; Armour, Trygve K.; Joppa, William R.; Maltais, Simon; Nelson, James A.; Wittwer, Erica.

In: Anesthesia and analgesia, Vol. 129, No. 1, 01.07.2019.

Research output: Contribution to journalArticle

Armour, Sarah ; Armour, Trygve K. ; Joppa, William R. ; Maltais, Simon ; Nelson, James A. ; Wittwer, Erica. / Use of Hydroxocobalamin (Vitamin B12a) in Patients With Vasopressor Refractory Hypotension After Cardiopulmonary Bypass : A Case Series. In: Anesthesia and analgesia. 2019 ; Vol. 129, No. 1.
@article{e3a460a6504044a6b87e2f1414b5b594,
title = "Use of Hydroxocobalamin (Vitamin B12a) in Patients With Vasopressor Refractory Hypotension After Cardiopulmonary Bypass: A Case Series",
abstract = "Hydroxocobalamin (vitamin B12a) is an emerging treatment for vasoplegic syndrome (VS) associated with cardiopulmonary bypass (CPB). Given its cost and scarcity, an institutional guideline for its use as a rescue treatment in cases of suspected VS was developed. Hemodynamic variables and vasopressor requirements were reviewed for a series of 24 post-CPB patients who received B12a. Favorable changes in hemodynamic parameters and vasopressor requirements were seen after B12a administration although guideline criteria for VS were inconsistently met. These findings support the continued study of B12a in patients with CPB-associated VS.",
author = "Sarah Armour and Armour, {Trygve K.} and Joppa, {William R.} and Simon Maltais and Nelson, {James A.} and Erica Wittwer",
year = "2019",
month = "7",
day = "1",
doi = "10.1213/ANE.0000000000003648",
language = "English (US)",
volume = "129",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Use of Hydroxocobalamin (Vitamin B12a) in Patients With Vasopressor Refractory Hypotension After Cardiopulmonary Bypass

T2 - A Case Series

AU - Armour, Sarah

AU - Armour, Trygve K.

AU - Joppa, William R.

AU - Maltais, Simon

AU - Nelson, James A.

AU - Wittwer, Erica

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Hydroxocobalamin (vitamin B12a) is an emerging treatment for vasoplegic syndrome (VS) associated with cardiopulmonary bypass (CPB). Given its cost and scarcity, an institutional guideline for its use as a rescue treatment in cases of suspected VS was developed. Hemodynamic variables and vasopressor requirements were reviewed for a series of 24 post-CPB patients who received B12a. Favorable changes in hemodynamic parameters and vasopressor requirements were seen after B12a administration although guideline criteria for VS were inconsistently met. These findings support the continued study of B12a in patients with CPB-associated VS.

AB - Hydroxocobalamin (vitamin B12a) is an emerging treatment for vasoplegic syndrome (VS) associated with cardiopulmonary bypass (CPB). Given its cost and scarcity, an institutional guideline for its use as a rescue treatment in cases of suspected VS was developed. Hemodynamic variables and vasopressor requirements were reviewed for a series of 24 post-CPB patients who received B12a. Favorable changes in hemodynamic parameters and vasopressor requirements were seen after B12a administration although guideline criteria for VS were inconsistently met. These findings support the continued study of B12a in patients with CPB-associated VS.

UR - http://www.scopus.com/inward/record.url?scp=85065064796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065064796&partnerID=8YFLogxK

U2 - 10.1213/ANE.0000000000003648

DO - 10.1213/ANE.0000000000003648

M3 - Article

C2 - 29979199

AN - SCOPUS:85065064796

VL - 129

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 1

ER -